Company to showcase NGS-based GMP QC strategies during the conference presentation, highlighting advanced applications for robust QC in CGT
KAISERAUGST, Switzerland, Sept. 9, 2025 /PRNewswire/ — Solvias, a global provider of chemistry, manufacturing, and controls (CMC) analysis, today announced that William Mauck, Team Lead Manager, Molecular Biology Lab at Solvias, and an expert in cell and gene therapy (CGT) quality and analytics, will present at the upcoming Cell & Gene Therapy International (CGTI) 2025, co-located with BioProcess International in Boston, Massachusetts, September 16–18. The annual conference brings together global experts to share cutting-edge insights on scaling next-generation therapies, with a spotlight on innovative manufacturing, rigorous analytics, and strategies to deliver safe, reliable treatments to patients worldwide.
The session, titled, “Multilayered QC in CGT: From Vector Fidelity to Epigenetic Regulation”, will highlight innovative analytical strategies that address some of the most pressing challenges in CGT manufacturing. His presentation will explore advanced large molecule characterization, vector insertion mapping, and adventitious virus detection using next-generation sequencing (NGS), along with the future potential of epigenetic testing.
“Multilayered quality control enables us to bring together powerful tools such as real-time genomic monitoring, precise vector validation, and early contaminant detection. These capabilities are critical to ensuring therapies remain consistent, safe, and effective throughout development,” said Mauck. “By integrating these next-generation methodologies, Solvias is helping C> developers to strengthen product reliability, meet the rising expectations of regulators, and ultimately scale cell and gene therapies responsibly, reliably, and with the confidence that patients deserve.”
Session Details
- Track: Manufacturing & Analytics: Strategies to scale autologous, allogeneic, and gene-edited therapies, emphasizing quality and return on investment.
- Title: Multilayered QC in CGT: From Vector Fidelity to Epigenetic Regulation.
- Date/Time: Wednesday, September 17, 2025 — 3:15 to 3:45 pm ET.
About Solvias
Solvias has 25 years of experience as a provider of chemistry, manufacturing, and control (CMC) analytics to the global life sciences industry. Its expert team combines decades of experience with regulatory expertise across small molecules, biologics, and cell and gene therapies. Solvias offers end-to-end solutions from raw material testing to drug product release and API development for small molecules. Headquartered near Basel, Switzerland, Solvias operates six global Centers of Excellence, all adhering to the highest ISO, cGMP, GLP, and FDA standards. For more information, visit solvias.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/solvias-to-present-at-cell–gene-therapy-international-2025-on-multilayered-quality-control-in-cgt-manufacturing-302550301.html
SOURCE Solvias
